ArticleKidney international reports2024

Response to Letter to the Editor From Bouwmeester RN et al.: "Eculizumab in Postransplant TMA: Unproven Benefit."

Federica Maritati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.